Please review the CME information below and click the acknowledgment checkbox
at the bottom of the page to begin this activity.
Release Date: September 24, 2010
Expiration Date: September 24, 2011
Target Audience
This educational activity is intended for oncologists and other healthcare providers involved and/or interested in the management of patients with multiple myeloma.
Overview
This brief case discussion examines the induction therapy options available for treating elderly patients with multiple myeloma.
Educational Objectives
Upon completion of this educational activity, participants should be able to:
- • Discuss the benefits of using maintenance therapy to treat patients with multiple myeloma after autologous stem cell transplantation
- • Review current and emerging induction therapy options for elderly patients with multiple myeloma
- • Discuss induction treatment strategies that maximize efficacy with minimal toxicity
Sponsorship Statement
This activity is jointly sponsored by Postgraduate Institute for Medicine (PIM) and prIME Oncology.
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
Postgraduate Institute for Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Method of Participation
There are no fees for participating and receiving CME credit for this activity. During the period September 24, 2010 through September 24, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question; 4) complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.
You may complete the post-test online at www.cmeuniversity.com. Click on “FIND POST-TEST/EVALUATION BY COURSE” on the navigation menu, and search by Course ID 7313. Upon successfully completing the post-test and evaluation, your certificate will be made available immediately.
Estimated time to complete activity: 0.50 hours
Support Statement
This activity is supported by an educational grant from Millennium, The Takeda Oncology Company.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr Palumbo has disclosed that he has received consulting fees from Celgene Corporation; Janssen Cilag; Amgen Inc; Merck & Co, Inc.; Millennium, The Takeda Oncology Company. He is on the speakers’ bureau for the Celgene Corporation; Janssen Cilag; Amgen Inc; Merck & Co, Inc.; Millennium, The Takeda Oncology Company.
The following PIM planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouses/life partners do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months
The employees of prIME Oncology have disclosed:
- • Lynne Smith, PhD (clinical) – no real or apparent conflicts of interest
- • Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
- • Brittany Brown (project management) – no real or apparent conflicts of interest
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Postgraduate Institute for Medicine; prIME Oncology; and Millennium, The Takeda Oncology Company do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM; prIME Oncology; or Millennium, The Takeda Oncology Company. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Media
Internet
Contact
For questions regarding this activity, please contact:
Postgraduate Institute of Medicine
367 Inverness Parkway
Englewood, Colorado 80112
303-799-1930
information@pimed.com
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the Internet.
